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ORIGINAL ARTICLE
There is a growing awareness of the importance
of behavioral and psychologic symptoms of de-
mentia (BPSD) among patients with dementia.
There are several reasons for this. First, BPSD are
major sources of a caregiver’s burden1,2 and also
the most important factor to consider when insti-
tutionalizing dementia patients.3 Second, despite
recent advances in “cognitive enhancing drugs”
fsuch as cholinesterase inhibitors, the capability o
modern medicine to improve cognitive functions
or delay the mental deterioration process in pa-
tients with dementia remains modest.4 Third, the
development of new generation atypical antipsy-
chotics and antidepressants brings substantial re-
rlief to the frequently encountered BPSD with fewe
motor, cognitive and autonomic toxicities to the
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Background/Purpose: Behavioral and psychologic symptoms of dementia (BPSD) are major sources of a
 caregiver’s burden and also the most important factor when considering the need for institutionalization
of dementia patients. BPSD occur in about 90% of patients with dementia. Studies comparing the BPSD in
the major types of dementia using unitary behavioral rating scales are limited. We studied BPSD in patients
with four major types of dementias from a memory clinic.
Methods: We recruited patients with dementia from our memory clinic from January 2003 to February 2004.
The Behavioral Pathology in Alzheimer’s Disease Rating Scale (BEHAVE-AD) was used to measure BPSD sever-
ity. Clinical Dementia Rating and Mini Mental State Examination were used to determine dementia severity.
Results: A total of 137 patients with four major types of dementia were recruited from 155 patients with
dementia who attended the clinic during the study period. The main dementia types identified were
Alzheimer’s dementia (AD) in 54.8%, vascular dementia (VaD) in 20.6%, frontotemporal dementia
(FTD) in 8.4%, dementia with Lewy bodies (DLB) in 4.5%, and other dementias in 11.6%. BPSD were
found in 92.0% of the patients but only 43.1% received psychotropic treatment. The relative risk of receiv-
ing psychotropic treatment for BPSD subscales paralleled the extent of caregivers’ burden as assessed
yby the BEHAVE-AD global rating. Type-specific BPSD, e.g. hallucination was identified for DLB, activit
disturbances for FTD, anxiety and phobias for AD and affective disturbance for VaD.
Conclusion: A strategy of targeting type-specific BPSD may be beneficial, such as environmental stimulus
control for DLB patients who are prone to have hallucinations, design of a pacing path for patients with
FTD who need support for symptoms of wandering and emotional support for patients with VaD who are
susceptible to depression. [J Formos Med Assoc 2006;105(7):556–562]
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elderly. Study of the nature, prevalence, clinical
typing, staging of severity and use of medications
in patients with BPSD is required to improve our
ability to treat and to care for patients with dif-
ferent types of dementia. BPSD are seen in about
90% of patients with dementia.5 Among the var-
ious types of dementia, BPSD have been best
studied in Alzheimer’s disease (AD). A review of
24 studies of psychosis involving more than
2200 patients found that delusion was reported
in 11–73% of all patients.6 There are several rea-
sons for such wide variation in the prevalence
rates of delusion as well as other BPSD, but the
most important is the lack of a consistent ap-
proach in defining and measuring BPSD. For ex-
ample, lower rates (22%) of delusions in AD
patients may be due to a sampling of BPSD occur-
ring only in the 4 weeks prior to the interview.7
The most prominent aspect of frontotemporal
dementia (FTD) is a profound change in person-
ality and social conduct compared with the pre-
morbid state. Verbal outbursts and inappropriate
activities were more common among FTD than
among AD patients.8 The most frequent BPSD
in dementia with Lewy bodies (DLB) are visual
hallucinations and delusions. Paranoid delu-
sions have been reported to occur in up to 80%
and hallucinations in up to 60% of patients with
DLB.9,10 Vascular dementia (VaD) is associated
with a high frequency of psychosis; delusions
may occur in up to 50% of patients11 and VaD is
also more likely to cause depression (45%) than
AD (17%).12 However, previous studies have not
compared BPSD among the major types of dem-
entia using a unitary behavioral rating scale. This
is very important since different behavioral rating
scales might have different emphasis or weight-
ing on various dimensions of BPSD. Furthermore,
the appearance and distribution of BPSD and
even the caregiver’s burden may be affected by
many factors including different cultural back-
grounds.13 This study obtained clinical informa-
tion from patients with various major types of
dementia from a single outpatient clinical popu-
lation, some of whom received psychotropic
medications for their BPSD.
Methods
Subjects
Patients with dementia attending a university hos-
pital memory clinic between January 2003 and
February 2004 were recruited. Patients with
dementia or suspected dementia in the hospital
were referred to the clinic for diagnosis and treat-
ment, and to facilitate caregiver support through
consultation and education. Patients who visited
the memory clinic received a thorough history tak-
cing and comprehensive physical and neurologi  
examinations. Mental status examinations were
also performed, which typically used a Mini
Mental State Examination (MMSE)14 and/or a
Cognitive Abilities Screening Instrument.
Neuroimaging, biochemical, and hemato-
logic studies were performed to rule out treatable
causes of dementia. In patients with atypical
findings, further detailed neuropsychologic stud-
ies were performed to assess general and spe-
ccific cognitive functions as well as psychiatri
symptoms.
Patients were grouped according to the fol-
lowing diagnostic criteria: NINCDS-ADRDA cri-
teria for AD;15 NINDS-AIREN criteria for VaD;16
McKeith et al’s17 consensus of diagnosis for DLB;
and Neary et al’s18 fcriteria for FTD. The use o
 psychotropic medications was recorded. Those
patients who failed to visit the memory clinic on
a regular basis or had too few visits for adequate
information gathering were excluded.
Assessment
After obtaining informed consent, the caregivers
were interviewed with the Behavioral Pathology in
Alzheimer’s Disease Rating Scale (BEHAVE-AD)19
to identify and to describe the BPSD of the
patient in the past 3 months. The BEHAVE-AD is
a 26-item observer rating scale containing seven
subscales, each rated 0–3 as follows:




(5) diurnal rhythm disturbance;
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(6) affective disturbance; and
(7) anxiety and phobias.
The 26th item is a global rating which can be
used as an index of the caregiver’s burden due to
the BPSD, in which 0 indicates “not at all troubling
to the caregiver or dangerous to the patient”; and
3 indicates “severely troubling or intolerable to the
caregiver or dangerous to the patient”. The Clinical
Dementia Rating (CDR)20 was used to evaluate and
to stage patients with dementia. MMSE was also
administered to assess patient’s cognitive functions.
Data analysis
Gender distribution, CDR scores, and the global
rating of the BEHAVE-AD were examined for dif-
ferences among patients with four types of dem-
entia using χ2 test. Differences in mean age and
years of education among the four dementia types
were analyzed using one-way ANOVA with Scheffé
post hoc pairwise comparison. ANCOVA was per-
formed with covariates of CDR scores and the ages
among the four dementia types to determine dif-
ferences among the adjusted BEHAVE-AD total
scores and subscales, using Scheffé method for post
hoc comparisons. Odds ratios of various subscales
were also computed for relative risks of using psy-
chotropic medications and for high caregivers’ bur-
den (patients whose global ratings of BEHAVE-AD
were 2 or 3). Spearman correlations were used to
explore relations among total scores or subscales
of the BEHAVE-AD, and for MMSE scores. All
analyses were performed with SPSS version 8.0
(SPSS Inc, Chicago, IL, USA).
Results
A total of 137 patients with four major types of de-
mentia out of 155 patients treated at the cclini
during the study period were included (Table 1).
The prevalence of different dementia types in
these patients were AD 54.8%, VaD 20.6%, FTD
8.4%, DLB 4.5%, and other dementias 11.6%.
rPatients in the heterogeneous category of “othe
dementias” were excluded from further analysis.
There were no significant differences among pa-
tients with different dementia types in the distri-
bution of sex (χ2 = 4.35, p f= 0.226) and years o
education (F=0.91, p=0.439). However, mean ages
were significantly different among types (F = 8.36,
p < 0.001). Scheffé post hoc t tests revealed tha
patients with FTD were much younger than
those with AD and VaD (both p < 0.001).
Scheffé post hoc tests also revealed a signifi-
cant difference in MMSE score between patients
with AD and FTD (F = 7.73, p < 0.001; Table 1).
However, the presence of BPSD may have prohib-
ited an adequate mental function test in some 
patients due to their uncooperative attitude. The
high rate of failure to take or complete the MMSE,
Table 1. Demographic and clinical characteristics of patients with dementia
Diagnosis AD VaD DLB FTD Total
Age at onset (yr)* 72.8 ± 9.1 75.1 ± 6.3 71.9 ± 5.9 61.8 ± 7.5 72.2 ± 8.9
Number (F/M) 85 (54/31) 32 (18/14) 7 (2/5) 13 (6/7) 137 (80/57)
Education (yr) 6.8 ± 5.3 8.5 ± 5.7 7.6 ± 5.6 8.5 ± 5.4 7.4 ± 5.4
CDR (1/2/3)† 43/37/5 – 0/4/3 5/1/7 52/52/33
BEHAVE-AD‡ 8.2 ± 2.1 13.5 ± 3.2 18.2 ± 4.4 9.7 ± 3.0 10.1 ± 3.9
GBEHAVE-AD‡ 0.75 ± 0.06 1.31 ± 0.07 1.86 ± 0.04 1.54 ± 0.1 1.01 ± 0.4
MMSE§ 16.0 ± 5.2 13.1 ± 6.3 8.0 ± 7.7 8.2 ± 6.6 14.7 ± 6.1
Medication⏐⏐ 28 (32.9%) 16 (50.0%) 6 (85.7%) 9 (69.2%) 59 (43.1%)
*ANOVA with Scheffé post hoc, F = 8.36, p < 0.001; †χ2 = 47.83 , p < 0.001; ‡ANCOVA adjusted with covariates of CDR scores and ages
with Scheffé post hoc, F = 8.644, p < 0.001 for BEHAVE-AD, and F = 6.00, p < 0.001 for GBEHAVE-AD; §ANOVA with Scheffé post hoc,
F = 7.73, p < 0.001; ⏐⏐χ2 = 13.00, p = 0.005. AD = Alzheimer’s disease; VaD = vascular dementia; DLB = dementia of Lewy bodies; FTD =
frontotemporal dementia; F/M = female/male; CDR = clinical dementia rating; BEHAVE-AD = adjusted mean ± standard deviation of total
scores; GBEHAVE-AD = adjusted mean ± standard deviation of global ratings of BEHAVE-AD; MMSE = mini mental state examination;
Medication = percentages of patients receiving psychotropic medications.
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especially in patients with DLB (57%) and FTD
(33%), prevented further comparative analysis of
MMSE data among groups.
The distribution of severity based on CDR
scores among different types of dementia was not
even (χ2 = 47.83, p < 0.001). Thus, further analy-
ses of the total scores or subscales of BEHAVE-AD
were done with adjusted ages and CDR scores.
The most frequent symptom dimension noted
among the subscales was activity disturbances.
More than two-thirds (67.2%) of patients had 
activity problems in which purposeless activity
took the lead (48.9%) followed by wandering
(43.8%) and inappropriate activities (30.7%). The
second most frequent symptom dimension was
paranoid and delusional ideation (62.0%) in
which suspiciousness/paranoia (42.3%) was the
most frequently encountered manifestation fol-
lowed by the delusion that “people are stealing
things” (40.1%). The third most frequent symp-
tom dimension was anxiety and phobias (58.4%)
with the most common anxiety arising from up-
coming events (36.5%). The fourth most frequent
symptom dimension was aggressiveness (48.2%)
in which verbal outbursts (36.5%) were more
frequent than physical threats or violence
(16.1%). Affective disturbance (35.8%), either as
tearful episodes (29.2%) or as depressed mood
(21.2%), was also found in some patients.
Hallucinations (30.7%), most frequently in the
form of visual hallucinations or their verbal,
physical or emotional responses (25.5%), were
also not infrequently noted.
Clinical type-specific BPSD patterns were read-
ily  identified. DLB was associated with a high
incidence of hallucinations (71.4%) and aggres-
fsiveness (71.4%), FTD with a high incidence o
 activity disturbances (92.3%), AD with a high
incidence of anxiety and phobias (61.2%) and
VaD with a high incidence of paranoid and delu-
sional ideation (71.9%) and affective disturbance
(46.9%; Table 2).
ANCOVA with adjusted CDR scores and ages
f revealed significant between-subject effects o
BEHAVE-AD total scores (F = 8.64, p < 0.001)
among different types of dementia (Table 1).
Scheffé post hoc test indicated that these differences
were greatest in DLB out of the four dementia
types and also that those for VaD were higher than
for AD and FTD (all p f< 0.001). Further analysis o
the subscale data disclosed significant differences
in aggressiveness (F = 11.10, p y < 0.001), activit
Table 2. Relative incidence and adjusted subscales of BPSD among types of dementia
AD VaD DLB FTD All
Paranoid/delusional ideation* 58.8% 71.9% 57.1% 61.5% 62.0%
2.5 ± 0.4 3.7 ± 0.7 4.7 ± 0.8 1.3 ± 0.1 2.8 ± 0.9
Hallucinations† 22.4% 46.9% 71.4% 23.1% 30.7%
0.8 ± 0.2 1.4 ± 0.3 4.4 ± 1.2 0.6 ± 0.1 1.1 ± 0.9
Activity disturbances‡ 62.4% 71.9% 57.1% 92.3% 67.2%
4 ± 0.4 1.6 ± 0.4 3.6 ± 0.9 3.2 ± 1.2 1.8 ± 0.9
Aggressiveness§ 34.1% 71.9% 71.4% 69.2% 48.2%
9 ± 0.4 3.1 ± 0.9 3.0 ± 0.9 2.2 ± 1.0 1.6 ± 1.1
Diurnal rhythm disturbances 28.2% 56.3% 42.9% 53.8% 38.0%
4 ± 0.0 0.9 ± 0.1 0.6 ± 0.0 0.8 ± 0.0 0.6 ± 0.2
Affective disturbance 36.5% 46.9% 28.6% 7.7% 35.8%
8 ± 0.1 1.1 ± 0.2 0.8 ± 0.1 0.3 ± 0.1 0.8 ± 0.2
Anxiety/phobias 61.2% 56.3% 57.1% 53.8% 58.4%
1.2 ± 0.1 1.4 ± 0.0 1.3 ± 0.1 0.9 ± 0.0 1.2 ± 0.2
*ANCOVA of subscales adjusted for CDR scores and ages (F = 3.11, p = 0.017) for paranoid/delusional ideation; †F = 7.09 and p < 0.001;
‡F = 8.36 and p < 0.001; §F = 11.10 and p < 0.001. AD = Alzheimer’s disease; VaD = vascular dementia; DLB = dementia of Lewy bodies;
FTD = frontotemporal dementia; % = incidence of subscales of BPSD in each subtype of dementia and in total number of patients;
mean ± SD of subscales in different types of dementia and in total number of patients.
disturbances (F = 8.36, p < 0.001), hallucinations 
(F = 7.09, p< 0.001) and the paranoid/delusional
ideation subscale (F= 3.11, p= 0.017). Post hoc tests
showed that the hallucinations subscale score
was highest in the DLB group, followed by VaD.
The activity disturbance subscale score was also
highest in DLB followed by FTD, although the rel-
ative incidence of such behavior was highest in
FTD. In contrast, FTD followed all other dementia
types in scores both for affective disturbance and
for anxiety/phobias subscales (both p < 0.001).
The mean total scores for the BEHAVE-AD
were significantly different between patients re-
ceiving (14.8 ± 8.8) and not receiving (6.5 ± 6.4)
psychotropic medications (F = 41.44, p < 0.001).
The relative risk of receiving psychotropic med-
ications in symptom subscales represented by
odds ratios were aggressiveness (2.81), para-
noid/delusional ideation (2.24), hallucinations
(2.12), diurnal rhythm disturbance (1.79), activ-
ity disturbances (1.56), affective disturbance
(1.28), and anxiety/phobias (1.07). Relative risk
of high caregiver’s burden paralleled the risk of
receiving psychotropic medications, with odds
ratios in the order of aggressiveness (17.57),
paranoid/delusional ideation (5.77), hallucina-
tions (4.26), diurnal rhythm disturbance (4.00),
activity disturbances (2.64), affective disturbance
(1.85), and anxiety/phobias (1.40).
MMSE scores showed significant negative corre-
lations with subscales of the BEHAVE-AD includ-
ing activity disturbances (n=105, Spearman rho
r=−0.358, p<0.001) and aggressiveness (r=−2.59,
p<0.001) but not with the total score (r=−0.155, 
p=0.115). CDR was positively correlated with total
BEHAVE-AD (n=137, Spearman rho r=0.379, p<
0.001) as well as with subscales of aggressiveness
(r=0.410, p< 0.001), activity disturbances (r=0.303,
p< 0.001), and hallucinations (r=0.254, p=0.003).
Discussion
FTD was characterized by much younger mean age
of onset than AD and other types of dementia
in this study, which is compatible with previous
observations.21 tThe FTD patient with the earlies
age of onset in this series was a 49-year-old male.
DLB accounts for only 4.5% (7/155) of demen-
tia f cases in this study. Although this series o
patients was from a memory clinic, its distribu-
tion might not represent the prevalence of demen-
tia in the general population. A previous study in
the UK found DLB to be the second most common
patho flogic cause of dementia, comprising 20% o
autopsy cases.22 An epidemiologic study in sub-
rurban London found that DLB accounted fo
10.9% of all types of dementias.23 An inpatient-
based study in Hong Kong, however, reported
a low prevalence rate of 2.9% DLB among all 
dementias in a psychogeriatric population,24 and
a community-based study in a Japanese rural
population found a DLB rate of 2.8%.25 These
findings suggest the possibility of ethnic differ-
ences in the prevalence rate of DLB, but neuro-
pathologic confirmation is required.
Although the manifestations of BPSD may be
influenced by a variety of factors, they are pri-
cmarily the results of underlying neurobiologi
cchanges in the brain. Previous clinicopathologi
correlation studies of BPSD had limited and in-
conclusive findings. Paranoid/delusional ideation
has been related to a temporal dysfunction.26
Neurobiologic studies of agitation and aggression
uncovered several relationships. Functional imag-
ing using 18F-fluorodeoxyglucose PET showed ttha
agitation and disinhibition correlated with de-
ccreased frontal and temporal cortical metaboli
rate.27 The extent of white matter injury and the
overall severity of the neuropsychiatric symptoms
as well as severity and depression were also well
correlated.28 Left frontal lobe lesion has been pro-
yposed to be pathogenic for depression, especiall
the lesions of the left anterior frontal lobe.29
Previous studies found patients with AD often
manifested motor behavior disturbance, aggres-
siveness, mood disturbances, and psychotic symp-
toms.30–33 In this study, we found patients with
yAD had relatively increased incidence of anxiet
and phobias. Transcultural or multiethnic studies
suggested that these manifestations had ethnic,
cultural, and social background dependencies.30–32
M.J. Chiu, et al
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More apathy and depression were reported in
western populations30,31 in contrast to more activ-
ity disturbances and aggressiveness in oriental 
patients.32,33 However, such comparisons may be
confounded by differences in clinical populations
including various severities or differences in pro-
fessional backgrounds of the interviewers.
One of the main findings of this study was the
delineation of subtype-specific patterns of BPSD.
For example, hallucination had the highest inci-
dence and severity in patients with DLB. Recurrent
visual hallucination is typically well-formed and is
one of the essential core features of DLB in the con-
sensus criteria of McKeith et al.17 Activity distur-
bances were noted in almost all patients (92.3%)
with FTD in this series, similar to a previous re-
port.8 Nevertheless, the early appearance of im-
paired language function in FTD could prevent the
expression of some BPSD such as affective distur-
bance, hallucinations or anxiety and phobias. On
the other hand, affective disturbance was most fre-
quently encountered in VaD (46.9%) in that nearly
one out of two patients exhibited such problems.34
Patients with DLB had the highest mean total
scores of BEHAVE-AD, caregiver’s burden, and inci-
dence of receiving psychotropic medications. On
the contrary, VaD had the highest scores in several
subscales such as aggressiveness, diurnal rhythm
disturbances or paranoid/delusional ideation in
addition to the aforementioned affective distur-
bance. VaD was not as aggressively treated as DLB
and FTD. The discrepancy should be further elu-
cidated. The presence of more caregiver-disturbing
or stress-producing BPSD such as aggressiveness,
paranoid/delusional ideation and hallucinations,
was associated with more frequent prescription of
psychotropic medications. This suggests that the
main purpose of using psychotropic medications
is to relieve the caregiver’s burden. In contrast,
BPSD with lower odds ratios of high caregiver’s
burden such as activity disturbances, affective dis-
turbance and anxiety-phobias, could be more eas-
ily handled by nonmedication methods.
The relationship between BPSD and cogni-
tive deficits, either in terms of cognition or func-
tional status in patients with dementia, was not 
yconclusive. However, psychotic symptoms, activit
disturbances, and aggressiveness seemed to have an
adverse effect on cognitive functions or vice versa.35
fAlthough this study included a total of 137 o
y155 patients with dementia who visited a memor
fclinic during the study period, the numbers o
 some dementia types such as DLB and FTD
wremained small due to their comparatively lo
yincidence. This is a major limitation of this stud
gand should be kept in mind when considerin
possible generalization of the findings.
Conclusion
The study found the subtype-specific BPSD in dif-
ferent types of dementia including hallucination
in DLB, activity disturbances in FTD, and affective
disturbance in VaD. The relative risk of psycho-
tropic medications was highly correlated with
tthe severity of caregivers’ burden, indicating tha
caregivers’ burden prompted physicians to pre-
scribe psychotropic medications for patients with
dementia. Since nonpharmacologic interventions 
for BPSD are helpful for caregivers of patients with
dementia, the need for different strategies of care-
giving for patients with different types of dementia
should be emphasized, including environmental
stimulus control for DLB patients who are prone
to having hallucinations, design of a pacing path
for patients with FTD who need support for symp-
toms of wandering, and emotional support for pa-
tients with VaD who are susceptible to depression.
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